Univercells Technologies
sells the scale-X platform, a fixed-bed perfusion bioreactor line scaling from a 0.5 m² scale-X nexo research system to a 600 m² scale-X nitro commercial-manufacturing configuration for vaccine and viral-vector production, engineered to overcome the scale-up limitations of traditional stirred-tank culture.
- Country
- Belgium
Commercial
scale-X fixed-bed perfusion, 0.5 m² (nexo) to 600 m² (nitro)
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| upstream-bioreactors | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| High-cell-density culture systems | upstream-bioreactors | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.